RAPT Therapeutics (RAPT) Competitors

Sana Biotechnology (NASDAQ:SANA) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.

Does the MarketBeat Community prefer SANA or RAPT?

RAPT Therapeutics received 68 more outperform votes than Sana Biotechnology when rated by MarketBeat users. However, 63.16% of users gave Sana Biotechnology an outperform vote while only 62.59% of users gave RAPT Therapeutics an outperform vote.

Company	Underperform	Outperform
Sana Biotechnology	Outperform Votes 24 63.16%	Underperform Votes 14 36.84%
RAPT Therapeutics	Outperform Votes 92 62.59%	Underperform Votes 55 37.41%

Do analysts prefer SANA or RAPT?

Sana Biotechnology currently has a consensus target price of $10.80, suggesting a potential upside of 325.20%. RAPT Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 175.23%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than RAPT Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
RAPT Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Do institutionals & insiders hold more shares of SANA or RAPT?

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are held by institutional investors. 30.1% of Sana Biotechnology shares are held by company insiders. Comparatively, 2.4% of RAPT Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, SANA or RAPT?

Sana Biotechnology has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

Does the media favor SANA or RAPT?

In the previous week, Sana Biotechnology had 1 more articles in the media than RAPT Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 5 mentions for RAPT Therapeutics. Sana Biotechnology's average media sentiment score of 1.03 beat RAPT Therapeutics' score of 0.26 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RAPT Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, SANA or RAPT?

RAPT Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$283.26M	-$0.88	-2.89
RAPT Therapeutics	$1.53M	94.25	-$116.80M	-$2.40	-0.45

Is SANA or RAPT more profitable?

Sana Biotechnology's return on equity of -84.22% beat RAPT Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-84.22%	-44.97%
RAPT Therapeutics	N/A	-89.10%	-76.13%

Summary

Sana Biotechnology beats RAPT Therapeutics on 11 of the 17 factors compared between the two stocks.